CompletedPhase 1ketamine

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

NCT ID

NCT02935725

Target Enrollment

22 participants

Start Date

2016-10

Est. Completion

2017-11

About This Study

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants

Conditions Studied

Schizophrenia

Interventions

•Low dose AUT00206 800mg
•High dose AUT00206 2000 mg
•Placebo
•Ketamine
•Saline

Eligibility

Sex:MALE

Age:18 Years - 45 Years

Healthy Volunteers:Yes

View full eligibility criteria

Inclusion Criteria:

* Male aged 18 to 45 years, inclusive at Visit 1.
* Healthy on the basis of medical history, psychiatric history, physical examination, vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and urinalysis within 6 weeks of Visit 2.
* Right-handed.
* Not a regular smoker (maximum 5 cigarettes per week or equivalent).

Exclusion Criteria:

* History of, or current condition of, migraine headaches or has undergone operations to the head.
* History of significant claustrophobia.

Study Locations (1)

University Of Manchester

London, United Kingdom